USANA Health Sciences, Inc. (NYSE:USNA) Director Sells $21,190.56 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert A. Fuller sold 674 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $31.44, for a total value of $21,190.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

USANA Health Sciences Stock Down 1.9 %

Shares of USANA Health Sciences stock opened at $32.49 on Thursday. The business’s fifty day simple moving average is $32.86 and its 200-day simple moving average is $36.08. The firm has a market cap of $619.32 million, a PE ratio of 11.48, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a 52 week low of $27.71 and a 52 week high of $50.32.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. As a group, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Institutional Trading of USANA Health Sciences

Large investors have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in USANA Health Sciences during the 4th quarter worth about $28,000. Safe Harbor Fiduciary LLC purchased a new stake in shares of USANA Health Sciences during the third quarter worth approximately $30,000. KBC Group NV raised its holdings in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after acquiring an additional 519 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in USANA Health Sciences during the 4th quarter worth approximately $83,000. Finally, Quantbot Technologies LP purchased a new stake in shares of USANA Health Sciences in the 4th quarter valued at approximately $132,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on USNA shares. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Finally, DA Davidson lowered their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.